A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

Clinical trial NCT01544348 · COMPLETED

Trial details

NCT number: NCT01544348
Sponsor: MedImmune LLC
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Allergic Asthma Atopic Dermatitis Allergic Rhinitis Healthy Volunteers

Start date: 2012-01-01
Primary completion: 2013-06-01
Enrollment: 295

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.